Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In B Cell Lymphoma B Cell Lymphoma for November/December 2020 Four-item prognostic index predicts survival in adult Burkitt lymphoma, Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies, ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma, Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL, Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL, More must reads B Cell Lymphoma for September/October 2020 Older age, r/r disease in lymphoma patients tied to increased COVID-19 death rate, Survey quantifies COVID-19’s impact on oncology, Napabucasin suppressed tumor growth in DLBCL cell lines, More must readsB Cell Lymphoma for March/April 2020 CAR T-cell therapy effective for r/r B-cell lymphoma of the GI tract, More must readsB Cell Lymphoma for January/February 2020 ECHELON-1 update: A+AVD bests ABVD in Hodgkin lymphoma, Adding lymphopenia component ‘improves’ FLIPI, REGN1979 shows good activity in pretreated aggressive B-NHL, More must readsB Cell Lymphoma for November/December 2019 CAR T-cell therapy advances in CLL, LOXO-305: Next-Gen BTK Inhibitor Safe and Effective in B-Cell Malignancies, Survival Data Reported From Largest CAR T Trial in B-Cell Lymphoma, Zanubrutinib achieved high response rate in del(17p) CLL cohort, Some MCL Patients Can Safely Stop Venetoclax-Ibrutinib, Study Suggests, More must readsPages1 2 3 last »
